5 Review of guidance

5.1 The data collection period is expected to end as outlined in the data collection arrangement, when more data from the ZUMA‑3 trial is available. Once enough evidence is available, the process for exiting the Cancer Drugs Fund will begin at this point and the review of the NICE guidance will start.

5.2 As part of the managed access agreement, the technology will continue to be available through the Cancer Drugs Fund after the data collection period has ended and while the guidance is being reviewed. This assumes that the data collection period ends as planned and the review of guidance follows the standard timelines described in section 6 of NICE's guide to the processes of technology appraisal.

Stephen O'Brien
Chair, appraisal committee
March 2023

  • National Institute for Health and Care Excellence (NICE)